ID 508 -
Kwas dokozaheksaenowy, Kwas eikozapentaenowy
PL: Kwas dokozaheksaenowy, Kwas eikozapentaenowy
EN: DHA+EPA - long chain omega 3 fatty acids
Pdf: eicosapentaenoic acid
Oświadczenie (2)
- budowę blokady dla lipidów w fotoreceptorów siatkówki oka, zdrowie oczu
- wspierać rozwój układu nerwowego u ludzi
- oka, mózgu i serca zdrowia
- i funkcje mózgu oko
- zdrowie oczu
- mózgu, oczu i nerwów rozwoju i funkcje
- błon struktury komórek
1. Charakterystyka żywności / składnika
The food constituent that is the subject of the health claims is long-chain n-3 polyunsaturated fatty acids (n-3 LCPUFAs), namely docosahexaenoic acid (DHA) in combination with eicosapentaenoic acid (EPA).
The n-3 LCPUFAs, EPA and DHA, are well recognised nutrients and are measurable in foods by established methods. They are well absorbed when consumed in the form of triglycerides. This evaluation applies to EPA and DHA from all sources with appropriate bioavailability in the specified amounts.
The Panel considers that the food constituent, DHA and EPA, which is the subject of the health claims, is sufficiently characterised.
2.3. Utrzymanie prawidłowego wzroku (ID 508, 510, 513, 519, 529, 540, 688, 2905, 4294)
The claimed effects are “eye health”, “eye, brain and heart health”, “brain, eye and nerve development and function”, “brain and eye function”, “support of human neurodevelopment”, “building block for lipids in the retina's photoreceptors; eye health”, and “membranes cell structure”. The Panel assumes that the target population is the general population. In the context of the proposed wordings and the clarifications provided, the Panel assumes that the claimed effects refer to the maintenance of normal vision.
A claim on DHA and maintenance of normal vision has already been assessed with a favourable outcome (EFSA Panel on Dietetic Products Nutrition and Allergies (NDA), 2010b).
Warunki i możliwe ograniczenia stosowania oświadczenia
125 - 500 mg
